表紙:生物製剤アウトソーシング市場-予測(2021年~2026年)
市場調査レポート
商品コード
1023148

生物製剤アウトソーシング市場-予測(2021年~2026年)

Biologics Outsourcing Services Market - Forecasts from 2021 to 2026

出版日: | 発行: Knowledge Sourcing Intelligence | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
生物製剤アウトソーシング市場-予測(2021年~2026年)
出版日: 2021年07月06日
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の生物製剤アウトソーシングサービス市場規模は、2019年の108億7,000万米ドルから2026年までには261億8,600万米ドルに達し、予想期間中に13.38%のCAGRで成長すると予測されています。

生物製剤とは、基本的には生体から調達した医薬品、または生体の成分で構成された医薬品を指します。これらの医薬品は、慢性疾患、癌、心血管疾患などの様々な疾患の治療にも使用されます。これらは、糖、タンパク質、核酸で構成されています。低分子医薬品と比較すると、生物製剤は非常にコストがかかりますが、患者により良い結果をもたらします。

当レポートでは、世界の生物製剤アウトソーシング市場について調査し、市場の概要と製品別、タイプ別、ソース別、用途別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション

第2章 調査手法

  • 調査データ
  • 前提条件

第3章 エグゼクティブサマリー

  • リサーチ・ハイライト

第4章 市場力学

  • 市場の促進要因
  • 市場の抑制要因
  • ポーターのファイブフォース分析
    • エンドユーザーの交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • 業界のバリューチェーン分析

第5章 生物製剤アウトソーシングサービス市場分析:商品別

  • イントロダクション
  • 抗体
  • 組換えタンパク質
  • ワクチン
  • その他

第6章 生物製剤アウトソーシングサービス市場分析:用途別

  • イントロダクション
  • ワクチンと治療法の開発
  • 血液および血液関連製品テスト
  • 細胞および遺伝子治療
  • 組織および組織関連製品テスト
  • 幹細胞調査

第7章 生物製剤のアウトソーシングサービス市場分析:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • その他
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • その他
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • 台湾
    • タイ
    • インドネシア
    • その他

第8章 競合環境と分析

  • 主要企業と戦略分析
  • 新興企業と市場の収益性
  • 企業合併・買収 (M&A)・契約・事業協力
  • ベンダー各社の競争力マトリックス

第9章 企業プロファイル

  • Lonza Group Ltd.
  • Charles River Laboratories
  • SGS SA
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec
  • Sartorius AG
  • Catalent, Inc.
  • Boehringer Ingelheim GmbH
  • Toxikon, Inc.
  • Eurofins Scientific SE
目次
Product Code: KSI061611088

The biologics outsourcing services market is projected to grow at a CAGR of 13.38% to reach US$26.186 billion by 2026 from US$10.870 billion in 2019. Biologics are essentially the drugs procured from living organisms or those which consist of the components of living organisms. These drugs are further used for the treatment of a range of diseases such as chronic diseases, cancer, cardiovascular diseases, etc. They are composed of sugar, proteins, and nucleic acid. When compared to small molecules drugs, biologics are much costlier but provides better results to the patient.

A major reason for the growth of this market is the growing need for research and development in the biologics outsourcing market and the advancement in biologic therapeutics.

The investment in research has increased rapidly. Globally, spending on research and development has increased in the past two decades. Every year the pharmaceutical industry develops a new variety of drugs. Data from the UNESCO Institute for Statistics (UIS) suggests that the global spending on research and development has reached almost US$ 1.7 trillion. According to the World Bank, East Asia and Pacific expenditure on research and development as a percentage of GDP accounts for 2.51 percent. The share of Korea remains the highest (4.81 percent) followed by Japan (3.26 percent) and China (2.19 percent) in the year 2018. In the US alone, pharmaceutical commerce spent $ 83 billion on Research and Development in 2019. According to UNESCO, North America and Western Europe spend the highest in R&D, followed by East Asia, South American, and Africa. Switzerland is the third-largest country to spend on R&D. With an ever-increasing expenditure on research and development, the global biologics outsourcing market is expected to grow.

Biologic therapeutics are considered to be the medicinal solutions of the future. Many countries are working upon the advancement of co-formulation strategies to establish biologic therapeutics. This will increase compliance, convenience, and accordance.

The investment and competition of the biologics outsourcing market are expected to drive the demand for this market in the forecast period.

Several players are making massive investments in the biologics outsourcing market across the world. The biologic outsourcing market is segmented into North America, Europe, Latin America, and the Asia Pacific region. North America is leading the biologic outsourcing market. Owing to a huge investment, wide population, and low-cost drug manufacturing, the Asia-Pacific region prevails as the fastest-growing biologics outsourcing market. With rapidly increasing investment, the European market is also expected to expand.

There's rapidly growing competition in the biologic outsourcing industries. The US owns the largest biologics market. Countries like India and China are providing a competitive edge in terms of lower prices and costs. Some of the leading competitors are Eurofins Scientific SE, WuXi AppTec, Lonza Group Ltd, SGS SA, Etc.

The rising chronic diseases, aging population, and investment are likely to accelerate the global biologics outsourcing market.

According to the world health organization, globally 41 million people die due to chronic diseases. A major proportion of these deaths are accounted to cardiovascular diseases. It claims 17.9 million lives annually, followed by cancer (9 million lives annually), respiratory diseases (3.9 million lives annually), and diabetes (1.6 million lives annually). According to the world health organization, "The number of people aged 65 or older is projected to grow from an estimated 524 million in 2010 to nearly 1.5 billion in 2050, with most of the increase in developing countries." According to the National Institute on Aging, approximately 79 percent of people, aged above 70 years, possess at least one of the seven chronic diseases- heart problem, diabetes, cancer, hypertension, stroke, arthritis, and respiratory disease. The growing number of people suffering from these chronic ailments is expected to drive the biologic outsourcing market. Biologic drugs are considered to be very useful when it comes to treating such diseases. Moreover, the companies are constantly investing in the research and development sector. Biocon Biologics is all set to invest Rupees 555 crores in 2021. Novartis AG, in Singapore, invested USD $700 million in its biologics sector and Squibb invested USD $900 million in 2019.

The rising COVID-19 Cases worldwide are also projected to positively impact the global biologics market.

Apart from social and economic disruptions, the disruption caused in the health care routine of the people by the pandemic is devastating. According to the World Health Organization, "nearly half of the world's 3.3 billion global workforces are at risk of losing livelihoods." This has created distress among the people, thereby having a very bad impact on their health. COVID-19 has also forced health care providers to alter their ways of treating patients. The rate of hospitalization has also increased. As the prolonged spread due to the virus is increasing, the infection spread is treated with biologics. Extensive research is taking place for the same. Until the development of vaccines, the COVID-19 treatment was solely dependent upon biological therapies.

Market Segmentation:

  • By Application

Vaccine and Therapeutics Development

Blood and Blood-Related Products Testing

Cellular and Gene Therapy

Tissue and Tissue-Related Products Testing

Stem Cell Research

  • By Offering

Antibodies

Recombinant Proteins

Vaccines

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • Germany
  • France
  • Others

The Middle East and Africa

  • Saudi Arabia
  • UAE
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Biologics Outsourcing Services Market Analysis, by Offering

  • 5.1. Introduction
  • 5.2. Antibodies
  • 5.3. Recombinant Proteins
  • 5.4. Vaccines
  • 5.5. Others

6. Biologics Outsourcing Services Market Analysis, by Application

  • 6.1. Introduction
  • 6.2. Vaccine & Therapeutics Development
  • 6.3. Blood and Blood-Related Products Testing
  • 6.4. Cellular and Gene Therapy
  • 6.5. Tissue and Tissue-Related Products Testing
  • 6.6. Stem Cell Research

7. Biologics Outsourcing Services Market Analysis, by Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. UK
    • 7.4.4. Others
  • 7.5. The Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Taiwan
    • 7.6.6. Thailand
    • 7.6.7. Indonesia
    • 7.6.8. Others

8. Competitive Environment and Analysis

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles

  • 9.1. Lonza Group Ltd.
  • 9.2. Charles River Laboratories
  • 9.3. SGS SA
  • 9.4. Thermo Fisher Scientific Inc.
  • 9.5. WuXi AppTec
  • 9.6. Sartorius AG
  • 9.7. Catalent, Inc.
  • 9.8. Boehringer Ingelheim GmbH
  • 9.9. Toxikon, Inc.
  • 9.10. Eurofins Scientific SE